These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12637666)

  • 1. Management of hyperphosphataemia in chronic renal disease: lessons from the past and future directions.
    Amato M; Aterini S
    Nephrol Dial Transplant; 2003 Apr; 18(4):848; author reply 848-9. PubMed ID: 12637666
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interaction between sevelamer and cyclosporin.
    Guillen-Anaya MA; Jadoul M
    Nephrol Dial Transplant; 2004 Feb; 19(2):515. PubMed ID: 14736993
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].
    Suzuki M
    Clin Calcium; 2004 Sep; 14(9):60-3. PubMed ID: 15577112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].
    Sesso R; Ferraz MB
    Rev Assoc Med Bras (1992); 2003; 49(1):103-8. PubMed ID: 12724821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.
    McIntyre CW; Patel V; Taylor GS; Fluck RJ
    Nephrol Dial Transplant; 2002 Sep; 17(9):1643-8. PubMed ID: 12198217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
    Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N; Nagano N
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should hyperphosphatemia be managed in dialysis patients?
    Block G; Uribarri J; Coladonato JA; Fan SL; Cunningham J; Nolan CR; Qunibi WY; Lindberg JS
    Semin Dial; 2002; 15(5):315-28. PubMed ID: 12358631
    [No Abstract]   [Full Text] [Related]  

  • 13. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
    Bover J; Ortiz-Herbener F; Ballarín J; Andrés E; Barceló P
    Nefrologia; 2005; 25 Suppl 2():100-8. PubMed ID: 16050412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with sevelamer in peritoneal dialysis].
    Ortiz A; Ríos F; Melero R; Reyero A; Gazapo R; Casado S
    Nefrologia; 2003; 23(5):432-6. PubMed ID: 14658169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium on trial: beyond a reasonable doubt?
    Nolan CR; Quinibi WY
    Kidney Int; 2003 Jan; 63(1):383; author reply 383-4. PubMed ID: 12472812
    [No Abstract]   [Full Text] [Related]  

  • 18. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.